| ASCO | American Society of Clinical Oncology |
| BMI | Body Mass Index |
| CAFs | Cancer-associated fibroblasts |
| CAT | Cancer-associated thrombosis |
| CrCl | Creatinine clearance |
| CRNMB | Clinically relevant non-major bleeding |
| CT | Computed tomography |
| DOACs | Direct oral anticoagulants |
| DVT | Deep venous thrombosis |
| EMT | Epithelial-to-mesenchymal transition |
| ESMO | European Society For Medical Oncology |
| FXI | Factor XI |
| GEM | Gemcitabine |
| FEMWAD | Gemcitabine with weight-adjusted dalteparin |
| GI | Gastrointestinal |
| GU | Genitourinary |
| Hb | Hemoglobin |
| IL-8 | Interleukin 8 |
| ITAC | International Initiative on Thrombosis and Cancer |
| IVE | Inferior vena cava |
| LMWH | Low-molecular-weight heparin |
| MB | Major bleeding |
| MVs | Microvesicles |
| NETs | Neutrophil extracellular traps |
| OS | Overall survival |
| PAI-1 | Plasminogen activator inhibitor type 1 |
| PAR | Protease-activated receptors |
| PC | Pancreatic cancer |
| PDAC | Pancreatic ductal adenocarcinoma |
| PDGF | Platelet-derived growth factor |
| PDPN | Podoplanin |
| PE | Pulmonary embolism |
| PFS | Progression-free survival |
| PF4 | Platelet factor 4 |
| PLT | Platelet |
| RBC | Red blood cell |
| TEC | Thromboembolic complications |
| TF | Tissue factor |
| TFPI | Tissue factor pathway inhibitor |
| TNF-a | Tumor necrosis factor a |
| UFH | Unfractionated heparin |
| VKA | Vitamin K antagonist |
| VTE | Venous thromboembolism |
| WBC | White blood cell |
| VEGF | Vascular endothelial growth factor |